Evidence map›Paper›PMID 22805498›Full record

Trial reportEuropean journal of clinical nutrition2012

Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation.

R E Grossmann, S M Zughaier, S Liu, R H Lyles, V Tangpricha

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of clinical nutrition, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 4 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00450073 nacompletednot on this map

Desktop Tanning Unit to Improve Vitamin D Status in Patients With Cystic Fibrosis and Short Bowel Syndrome: A Pilot Study

TypeinterventionalSponsorAtlanta VA Medical CenterRan2006 to 2011Enrolled30ConditionsCystic FibrosisArmsergocalciferol (vitamin D2), Sperti Del Sol Lamp, Vitamin D3
NCT01880346 phase4completednot on this mapstarted 2013, after this paper: background citation

Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil

TypeinterventionalSponsorEmory UniversityRan2013 to 2015Enrolled17ConditionsCystic FibrosisArmsVitamin D Powder, Vitamin D Oil
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Vitamin D supplementation for cystic fibrosis.The Cochrane database of systematic reviews · 2014
    Pooled it
  4. Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2014
    Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Randomized controlled trial of calcitriol in severe sepsis.American journal of respiratory and critical care medicine · 2014
    Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A Single Oral Vitamin DInternational journal of molecular sciences · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

R E GrossmannNutrition Health Sciences Program, Emory Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA.
S M Zughaier
S Liu
R H Lyles
V Tangpricha
Emory University · USChildren's Healthcare of Atlanta · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalTL1TR000456 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$1.2M
Atlanta Clinical and Translational Science Institute (TL1)TL1RR025010 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$1.1M
Role of T-cells in Osteoporosis in Women Undergoing Surgical MenopauseK23AR054334 · NIAMS · EMORY UNIVERSITY · PI TANGPRICHA, VIN · 2007 to 2011
$641k
NCATS NIH HHS TL1 TR000456NCATS NIH HHS UL1 TR000454NCRR NIH HHS TL1 RR025010NCRR NIH HHS UL1 RR025008NIAMS NIH HHS K23 AR054334NIAMS NIH HHS K23AR054334
6 · The paper itself

Abstract

Patients with cystic fibrosis (CF) suffer from chronic lung infection and inflammation leading to respiratory failure. Vitamin D deficiency is common in patients with CF, and correction of vitamin D deficiency may improve innate immunity and reduce inflammation in patients with CF. We conducted a double-blinded, placebo-controlled, randomized clinical trial of high-dose vitamin D to assess the impact of vitamin D therapy on antimicrobial peptide concentrations and markers of inflammation. We randomized 30 adults with CF hospitalized with a pulmonary exacerbation to 250,000 IU of cholecalciferol or placebo, and evaluated changes in plasma concentrations of inflammatory markers and the antimicrobial peptide LL-37 at baseline and 12 weeks post intervention. In the vitamin D group, there was a 50.4% reduction in tumor necrosis factor-α (TNF-α) at 12 weeks (P<0.01), and there was a trend for a 64.5% reduction in interleukin-6 (IL-6) (P=0.09). There were no significant changes in IL-1β, IL-8, IL-10, IL-18BP and NGAL (neutrophil gelatinase-associated lipocalin). We conclude that a large bolus dose of vitamin D is associated with reductions in two inflammatory cytokines, IL-6 and TNF-α. This study supports the concept that vitamin D may help regulate inflammation in CF, and that further research is needed to elucidate the potential mechanisms involved and the impact on clinical outcomes.

Indexed as

Acute-Phase ProteinsAdultAntimicrobial Cationic PeptidesCathelicidinsCystic FibrosisDouble-Blind MethodFemaleHumansInflammationInterleukinsLinear ModelsLipocalin-2LipocalinsMaleProto-Oncogene ProteinsTumor Necrosis Factor-alphaAcute-Phase ProteinsAntimicrobial Cationic PeptidesCathelicidinsInterleukinsLCN2 protein, humanLipocalin-2LipocalinsProto-Oncogene ProteinsTumor Necrosis Factor-alphaVitamin D

Identifiers

PMID22805498
PMCPMC3638806
OpenAlexW2011630862

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.